- Nutanix reported a very strong Q2 with revenue coming in over 5% above consensus and ACV run-rate billings growing 28%.
- The company provided Q3 guidance which includes ACV run-rate billings growth of mid-20% range, which could end up being a little conservative.
- Recent focus on ACV billings and additional opportunities to further penetrate the Global 2K customer base yield bullish long-term growth potential.
- Valuation of only 3.5x FY22 revenue seems cheap considering the potential long-term revenue growth profile.
For further details see:
Nutanix: Post-Earnings Correction Not Warranted; Prepare For Upward Re-Rating